open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22
Get Citation

Chemotherapy based on liposomal doxorubicin (Myocet®) in metastatic breast cancer after prior first-line treatment with anthracycline

Jerzy Hanslik

open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

Abstract

Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant therapeutic problem. The abundance of available systemic treatment regimens and the possibility of applying different therapies pose before the physician a difficult task of employing the optimal treatment approach. At the same time, good therapeutic results and ever better tolerance for systemic treatment lead to female patients receiving a large number of chemotherapy lines. One of the options in recent years is the treatment with the use of liposomal doxorubicin. A case report is presented of a female patient who received secondline therapy with liposomal doxorubicin in combination with cyclophosphamide after prior treatment with anthracyclines.
Onkol. Prak. Klin. 2010; supl. A: A28–A30

Abstract

Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant therapeutic problem. The abundance of available systemic treatment regimens and the possibility of applying different therapies pose before the physician a difficult task of employing the optimal treatment approach. At the same time, good therapeutic results and ever better tolerance for systemic treatment lead to female patients receiving a large number of chemotherapy lines. One of the options in recent years is the treatment with the use of liposomal doxorubicin. A case report is presented of a female patient who received secondline therapy with liposomal doxorubicin in combination with cyclophosphamide after prior treatment with anthracyclines.
Onkol. Prak. Klin. 2010; supl. A: A28–A30
Get Citation

Keywords

metastatic breast cancer; chemotherapy; liposomal doxorubicin

About this article
Title

Chemotherapy based on liposomal doxorubicin (Myocet®) in metastatic breast cancer after prior first-line treatment with anthracycline

Journal

Oncology in Clinical Practice

Issue

Vol 6, Supp. A (2010)

Pages

28-30

Published online

2010-11-22

Keywords

metastatic breast cancer
chemotherapy
liposomal doxorubicin

Authors

Jerzy Hanslik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl